A dynamic map for learning, communicating, navigating and improving therapeutic development
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Drug discovery and development is a highly challenging process ( Nat. Rev. Drug Discov. 9 , 203–214; 2010) 1 . Its common characterization as a 'pipeline' connotes consistent unidirectional flow of a candidate therapeutic in unchanged form from basic research discovery to drug to utilization, in stark contrast to the diverse web of failure-prone iterative learning loops that, in reality, must be traversed by scientists, physicians, regulators, payers and patients to develop and use new treatments 2 . This deeply engrained misnomer contributes to the lack of public understanding of the drug development process, with implications for science and public policy, and leads to actions that may fail to improve, and perhaps even worsen, the process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Cited by
Exome sequencing of 20,791 cases of type 2 diabetes and 24,440 controls
Platform, B. G., Flannick, J., DiscovEHR Collaboration, CHARGE, LuCamp, ProDiGY, GoT2D, ESP, SIGMA-T2D, T2D-GENES, et al. (2019) · Nature · doi:10.1038/s41586-019-1231-2 · Cited by 304
Artificial Intelligence for Drug Discovery: Are We There Yet?
Hasselgren, C., & Oprea, T. I. (2024) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-040323-040828 · Cited by 236
“discovery is often called a ‘pipeline,’ which suggests a unidirectional transition from hit/lead to candidate and marketed drug, supported by basic and clinical research (1).”
BackgroundOpportunities and challenges in translational science
Austin, C. P. (2021) · Clinical and Translational Science · doi:10.1111/cts.13055 · Cited by 188
Self-citationWagner, J. A., Dahlem, A. M., Hudson, L. D., Terry, S. F., Altman, R. B., Gilliland, C. T., DeFeo, C., & Austin, C. P. (2018) · Clinical and Translational Science · doi:10.1111/cts.12531 · Cited by 45
Self-citationAlternative strategies in cardiac preclinical research and new clinical trial formats
Kreutzer, F. P., Meinecke, A., Schmidt, K., Fiedler, J., & Thum, T. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvab075 · Cited by 36
“183,184 Nevertheless, the traditional structure of clinical trials has provided additional room for improved success rates and reduced costs.”
Background
Metadata
- Authors
- Wagner, J., Dahlem, A. M., Hudson, L. D., Terry, S. F., Altman, R. B., Gilliland, C. T., DeFeo, C., & Austin, C. P.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2017-12-22
- Volume
- 17
- Issue
- 2
- Pages
- 150-150
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2779518696
- Cited by
- 56
- References
- 1
- FWCI
- 7.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.